2024
Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour E. Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Frontiers In Oncology 2024, 14: 1455378. PMID: 39634261, PMCID: PMC11615674, DOI: 10.3389/fonc.2024.1455378.Peer-Reviewed Original ResearchMatching-adjusted indirect comparisonChronic-phase chronic myeloid leukemiaChronic myeloid leukemiaT315I mutationCP-CMLMyeloid leukemiaTyrosine kinase inhibitor therapyIndirect comparisonsResponse rateBaseline responsesSecond-generation TKIsT315I mutation statusKinase inhibitor therapyThird-line therapyMedical literature databasesInhibitor therapyMutation subgroupsMutation statusPatient-level dataEfficacy outcomesBaseline characteristicsMMR rateProportion Z testClinical trialsCumulative rateALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy
Ashaye A, Chalandon Y, Boissel N, Fazioli K, Wang B, Aldoss I, Huang F, Leonard J, Szabo N, McCloskey C, Nair S, Dalal M, Hennessy M, Yeh T, Martinelli G, Badar T, Kantarjian H, Ribera J, Jabbour E. ALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s270-s271. DOI: 10.1016/s2152-2650(24)01111-x.Peer-Reviewed Original ResearchMinimal residual diseasePh+ acute lymphoblastic leukemiaAcute lymphoblastic leukemiaMRD-negative CRFirst-line therapyLong-term EFSIndividual patient dataComplete remissionFirst-lineMRD analysisLymphoblastic leukemiaPrognostic indicatorAdult patientsPrognostic indicators of long-term survivalDiagnosed Ph+ ALLPhiladelphia chromosome-positive acute lymphoblastic leukemiaMinimal residual disease levelsMinimal residual disease statusMRD-negative complete remissionIndicators of long-term survivalIndividual patient data analysisAchievement of CRStudy-level meta-analysisKaplan-Meier methodLog-rank testMinimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy
Ashaye A, Chalandon Y, Boissel N, Fazioli K, Wang B, Aldoss I, Huang F, Leonard J, Szabo N, McCloskey C, Nair S, Dalal M, Hennessy M, Yeh T, Martinelli G, Badar T, Kantarjian H, Ribera J, Jabbour E. Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s161. DOI: 10.1016/s2152-2650(24)00430-0.Peer-Reviewed Original ResearchUpdate and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research
Oerlemans S, de Rooij B, Bennink C, Bullinger L, Broijl A, D’Agostino M, Laane E, Lupo-Stanghellini M, Perrot A, Wester R, Cursaru V, Scheurer H, Vesseur J, Dalal M, Sen R, Stamm T, Ludwig H, Sonneveld P. Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research. Haematologica 2024, 109: 1956-1959. PMID: 38299690, PMCID: PMC11141662, DOI: 10.3324/haematol.2023.284282.Peer-Reviewed Original Research
2023
POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)
Jabbour E, Huang F, Zoratti M, Rutherford M, Moradian H, Dalal M, Ashaye A, Gordan L. POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS). Clinical Lymphoma Myeloma & Leukemia 2023, 23: s176. DOI: 10.1016/s2152-2650(23)00549-9.Peer-Reviewed Original ResearchCML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)
Jabbour E, Huang F, Zoratti M, Rutherford M, Moradian H, Dalal M, Ashaye A, Gordan L. CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS). Clinical Lymphoma Myeloma & Leukemia 2023, 23: s338-s339. DOI: 10.1016/s2152-2650(23)01135-7.Peer-Reviewed Original Research